Abstract: The present invention relates to a method of determining the trapped volume and the trapped aqueous volume of a plurality of liposomes in a liposomal composition. The method can be used for calculating the concentration of an active pharmaceutical ingredient entrapped within the liposomes and for quality assurance of a pre-formed liposomal composition.

Abstract: The technology subject of the present application concerns a novel class of fused nanocrystal molecules having unique electronic properties. The application further contemplates methods for their preparation and methods of their use.

Abstract: Disclosed herein are genetically modified plants having altered biological activity of 3-?-hydroxysteroid dehydrogenase/isomerase (GAME25), or 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plants have an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof. Further disclosed herein are genetically modified plants having altered expression of a gene encoding a 3-?-hydroxysteroid dehydrogenase/isomerase (GAME25), or a 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plant has an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof.

Abstract: Methods of treating fragile X syndrome by administering agents that reduce expression or function of various proteins are provided. Methods of determining suitability to be treated by the methods of the invention are also provided.

Abstract: Methods of reactivating transcription of a fragile X mental retardation 1 (FMR1) gene and treating FMR1-associated diseases are provided. Compositions and kits for doing same are also provided.

Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAK1) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.

Abstract: Provided are methods, compositions and kits employing cellulose nanocrystals for hair-straightening treatment. Also provided are methods, compositions and kits employing a resilin, for hair-straightening treatment and/or for maintenance of straightened hair following a hair-straightening treatment.

Abstract: Provided are systems, compositions, methods and devices for manufacturing artificial skin substitutes and related products mimicking the morphology and appearance of human skin. Applications of the invention pertain to the fields of regenerative medicine and pharma with products that can support tissue replacement and tissue engineering. The most immediate applications pertain to the field of cosmetics with the development of pigmented compositions that can be incorporated in various skin care and cosmetic foundation products.

Abstract: Methods of treating lipotoxicity in the lungs by administering a metabolic regulator are provided.

Abstract: The present invention provides arylated fenchone derivatives, compositions comprising them, processes for their preparation and uses thereof.

Abstract: A method comprising: receiving, as input, training images, wherein at least a majority of the training images represent normal data instances; receiving, as input, a target image; extracting (i) a set of feature representations from a plurality of image locations within each of the training images, and (ii) target feature representations from a plurality of target image locations within the target image; calculating, with respect to a target image location of the plurality of target image locations in the target image, a distance between (iii) the target feature representation of the target image location, and (iv) a subset from the set of feature representations comprising the k nearest the feature representations to the target feature representation; and determining that the target image location is anomalous, when the calculated distance exceeds a predetermined threshold.

Abstract: Provided is a formulation and method for increasing bioavailability of an orally administered drug.

Abstract: Provided herein are heteroaryl compounds, for example, a compound of Formula I or IA, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, ameliorating, or preventing one or more symptoms of a disorder, disease, or condition mediated by a casein kinase 1 (CK1), an interleukin-1 receptor associated kinase (IRAK1), or a cyclin-dependent kinase 9 (CDK9).

Abstract: A process for preparing a granular composite adsorbent, that includes combining poly(diallyl dimethyl ammonium halide) and a clay mineral in water, maintaining the mixture under stirring, recovering a wet mass, forming the wet mass into granules and drying the granules to obtain the granular adsorbent having surface layer with positive zeta potential. The granular material and methods using the granular material in water treatment are also disclosed.

Abstract: A composition of matter is provided comprising a devitalized, acellular tissue-derived scaffold seeded with differentiated cells, particularly pancreatic islet cells, wherein the cells can maintain cell-specific function or structure in culture on the scaffold. Methods of generating same and uses thereof are also provided.

Abstract: Methods of inhibiting reactive oxygen species production by neutrophils or treating neutrophil-mediated inflammation in a subject by contacting the neutrophils with or administering an agent selected from a cyclin dependent kinase 4 (CDK4) inhibitor, a cyclin dependent kinase 6 (CDK6) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, a proto-oncogene tyrosine-protein kinase Src (SRC) inhibitor and a sodium (Na) channel blocker are provided. Pharmaceutical compositions comprising a nanoparticle, the agent and a neutrophil targeting peptide are also provided.

Abstract: The disclosure concerns viscous or gelled delivery systems based on oily nano-domains dispersed in a viscosified/gelled continuous aqueous phase, and suitable for prolonged and/or sustained topical delivery of various active compounds.

Abstract: The present invention provides oligonucleotides capable of binding to and modulating the splicing of the pre-mRNA of the CFTR gene, including compositions comprising the oligonucleotides, and uses thereof, such as for suppressing the inclusion of a cryptic exon between exon 22 and 23 as a result of the mutation 3849+10 Kb C-to-T, optionally in combination with additional CF therapeutics.

Abstract: Natural killer (NK) cell killing of various tumors is inhibited in the presence of ligands of TIGIT, an inhibitory receptor present on all human NK cells and on various T cells. Monoclonal antibodies that recognize TIGIT and inhibit its suppressive activity on T-cells are provided as well as pharmaceutical compositions comprising them and methods for their use in cancer immunotherapy and in diagnosis and treatment of immune disorders.

Abstract: The invention provides compounds and uses thereof in the treatment and prevention of diseases and conditions associate with or aggravated by impaired mitophagy or oxidative stress, and methods of their preparation.